Latest period
$85.38B
YoY change
+33.4%
5Y CAGR
+16.1%
Peak year (2025)
$85.94B
Latest annual
$85.94B
Total Liabilities history chart for Eli Lilly (LLY) from 1985 to 2025
Latest: $85.94B
Total Liabilities growth chart for Eli Lilly (LLY) from 1985 to 2025
Latest: +33.4%
Total Liabilities history table for Eli Lilly (LLY) from 1985 to 2025
| 2025 | $85.94B | +33.4% | +$21.50B | ||
| 2024 | $64.44B | +21.3% | +$11.30B | ||
| 2023 | $53.14B | +37.3% | +$14.43B | ||
| 2022 | $38.71B | -2.4% | −$936.80M | ||
| 2021 | $39.65B | -2.8% | −$1.16B | ||
| 2020 | $40.81B | +11.5% | +$4.22B | ||
| 2019 | $36.59B | +10.9% | +$3.59B | ||
| 2018 | $33.00B | -0.9% | −$313.80M | ||
| 2017 | $33.31B | +34.7% | +$8.59B | ||
| 2016 | $24.73B | +17.9% | +$3.75B | ||
| 2015 | $20.98B | +0.3% | +$59.10M | ||
| 2014 | $20.92B | +18.8% | +$3.31B | ||
| 2013 | $17.61B | -10.3% | −$2.02B | ||
| 2012 | $19.63B | -2.5% | −$499.20M | ||
| 2011 | $20.12B | +8.3% | +$1.54B | ||
| 2010 | $18.59B | +3.6% | +$653.00M | ||
| 2009 | $17.94B | -20.2% | −$4.54B | ||
| 2008 | $22.48B | +68.1% | +$9.11B | ||
| 2007 | $13.37B | +21.8% | +$2.40B | ||
| 2006 | $10.97B | -20.4% | −$2.81B | ||
| 2005 | $13.79B | -1.1% | −$158.20M | ||
| 2004 | $13.95B | +17.1% | +$2.03B | ||
| 2003 | $11.91B | +10.6% | +$1.14B | ||
| 2002 | $10.77B | +15.4% | +$1.44B | ||
| 2001 | $9.33B | +7.9% | +$686.20M | ||
| 2000 | $8.64B | +10.6% | +$831.70M | ||
| 1999 | $7.81B | -4.3% | −$353.70M | ||
| 1998 | $8.17B | +5.1% | +$394.10M | ||
| 1997 | $7.77B | -5.3% | −$435.30M | ||
| 1996 | $8.21B | -8.6% | −$772.80M | ||
| 1995 | $8.98B | -1.9% | −$171.90M | ||
| 1994 | $9.15B | +81.1% | +$4.10B | ||
| 1993 | $5.05B | +33.7% | +$1.27B | ||
| 1992 | $3.78B | +13.4% | +$448.20M | ||
| 1991 | $3.33B | -9.3% | −$342.80M | ||
| 1990 | $3.68B | +75.8% | +$1.58B | ||
| 1989 | $2.09B | +2.6% | +$53.50M | ||
| 1988 | $2.04B | -7.9% | −$174.90M | ||
| 1987 | $2.21B | +19.2% | +$356.10M | ||
| 1986 | $1.86B | +18.5% | +$290.20M | ||
| 1985 | $1.57B | — | — |
- 2025$85.94B+33.4%
- 2024$64.44B+21.3%
- 2023$53.14B+37.3%
- 2022$38.71B-2.4%
- 2021$39.65B-2.8%
- 2020$40.81B+11.5%
- 2019$36.59B+10.9%
- 2018$33.00B-0.9%
- 2017$33.31B+34.7%
- 2016$24.73B+17.9%
- 2015$20.98B+0.3%
- 2014$20.92B+18.8%
- 2013$17.61B-10.3%
- 2012$19.63B-2.5%
- 2011$20.12B+8.3%
- 2010$18.59B+3.6%
- 2009$17.94B-20.2%
- 2008$22.48B+68.1%
- 2007$13.37B+21.8%
- 2006$10.97B-20.4%
- 2005$13.79B-1.1%
- 2004$13.95B+17.1%
- 2003$11.91B+10.6%
- 2002$10.77B+15.4%
- 2001$9.33B+7.9%
- 2000$8.64B+10.6%
- 1999$7.81B-4.3%
- 1998$8.17B+5.1%
- 1997$7.77B-5.3%
- 1996$8.21B-8.6%
- 1995$8.98B-1.9%
- 1994$9.15B+81.1%
- 1993$5.05B+33.7%
- 1992$3.78B+13.4%
- 1991$3.33B-9.3%
- 1990$3.68B+75.8%
- 1989$2.09B+2.6%
- 1988$2.04B-7.9%
- 1987$2.21B+19.2%
- 1986$1.86B+18.5%
- 1985$1.57B—
Total Liabilities values are taken from Eli Lilly's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's latest reported total liabilities is $85.38B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Eli Lilly (LLY) most recent annual total liabilities stands at $85.94B (2025) – surged 33.4% year-over-year.
Eli Lilly total liabilities has grown on net over the period, with a +16.1% compound annual growth rate over 2020–2025 (5 years).
Across the available history, total liabilities reached its high of $85.94B in 2025 and its low of $1.57B in 1985.
Eli Lilly Total Liabilities by Year
Eli Lilly Total Liabilities 2025: $85.94B
In 2025, Eli Lilly reported total liabilities of $85.94B, surged 33.4% from 2024. This figure represents the highest annual value in the available history.
Eli Lilly Total Liabilities 2024: $64.44B
Eli Lilly total liabilities in 2024 was $64.44B, grew 21.3% from 2023.
Eli Lilly Total Liabilities 2023: $53.14B
2023's total liabilities for Eli Lilly came in at $53.14B, surged 37.3% from 2022.
Eli Lilly Total Liabilities 2022: $38.71B
Eli Lilly posted total liabilities of $38.71B in 2022, edged down 2.4% below 2021.
Eli Lilly Total Liabilities 2021: $39.65B
Eli Lilly total liabilities in 2021 was $39.65B.
See more financial history for Eli Lilly (LLY).
Sector peers by Total Liabilities
Healthcare peers of Eli Lilly (LLY), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $56.81B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation